Table 3 Characteristics of eligible trials for osteosarcoma only

Salesh RA., et al., Cancer 65:861-5.

Etoposide 72-h i.v 600 mg/m². Cyclophosphamide 300 mg/m2 every 12 hours for a total dose of 1800 mg/m2.

15 (88%) CR or PR

Kleinerman ES, et al J. Clin. Oncol. 10, 1310-6. [57]

L-MTP-PE 2 mg/m² infused during a 1-h period twice a wk for 12 wks, then once a wk for 12 wks.

Not mentioned

Kleinerman ES, et al Am J Clin Oncol. 18(2):93-9. [58]

L-MTP-PE, 2 mg/m², i.v over a 1-h twice a wk for 12 wks in 12 pts (Group 1). 16 pts (Group 2) had 2 mg/m² L-MTP-PE twice a wk for 12 wks, then once a wk for 12 wks, for a total of 24 wks.

2 (6%) SD

Kleinerman ES, et al J. Immunother. Emphasis Tumor Immunol., 17, 181-93. [59]

IFO 1.8 g/m² for 5 days every 21 days for up to 8 cycles. L-MTP-PE twice weekly for 12 weeks, then once weekly for 12 weeks

Not mentioned

Harris MB, et al Med Ped Oncol 24, 87-92. [60]

Two courses of ifosfamide (2400 mg/m² × 5 days) administered 3 wks apart

Stratum 1: 1 (11%) CR, 8 (24%) PR

Stratum 2: 1 (3%) CR, 2 (7%) PR

Patel SR, et al Cancer; 78:741-4. [61]

Paclitaxel 175 mg/m² 24-h i.v

0% OR

Gentet JC, et al Eur J Cancer, Vol. 33, No. 2, 232-7 [62]

Two courses of IFO 3 g/m²/day and etoposide 75 mg/m²/day for 4 days.

6 (23%) CR, 7 (25%) PR, 5 (23%) SD

Worth LL, et al Clin Cancer Res. 3(10):1721-9. [63]

IL-1alpha followed by ICE daily for 5 days/3 wks.

3 (34%) PR, 1 (11%) SD

Voûte PA, et al Annals of Oncology 10: 1211-8. [64]

IFO 3 g/m²/dl-2, DOX 25 mg/m²/dl-3 i.v. bolus and CDDP 100 mg/m²/dl.

5 year survival was 62% in limb-non-metastatic, 41% in axial skeletal and 16% in limb metastatic patients.

Fagioli F, et al Journal of Clinical Oncology, Vol 20, Issue 8:2150-6 [65]

High-dose chemotherapy consisted of carboplatin and etoposide followed by stem-cell rescue.

25 (78%) CR, 6 (19%) PD,

3 year OS 20%

3 year DFS 12%

Laverdiere C, et al Cancer; 98:832-40. [66]

Trabectedin 1500 micro g/m² as a 24-h i.v every 3 wks.

0% OR

McTiernan A, et al. Sarcoma, Vol. 8, No. 2/3, 71-6. [67]

Docetaxel 100 mg/m² 1-h i.v every 3 wks

1 (7%) PR, 2 (14%) SD

Ferrari S et al J Clin Oncol 23:8845-52. [68]

Two blocks of high-dose IFO (15 g/m²), MTX (12 g/m²), CDDP (120 m g/m²), and DOX (75 m g/m²)

5-year EFS 64% and OS 77%

Arpaci F, et al Cancer; 104:1058-65. [69]

2 cycles of CDDP, DOX, and IFO followed by HDC and APBSCT.

3 year: OS was 83% & 70% DFS

McTiernan A, et al Pediatr Blood Cancer. 46(3):345-50. [70]

IFO 2.5 g/m² etoposide 150 mg/m² and DOX 20 mg/m² on days 1-3, every 21 days, with interval MTX 12 g/m² given on day 14, for a maximum of 8 cycles.

0% OR

Seibel NL, et al Cancer 2007; 109:1646-53. [71]

Topotecan daily x5 followed by chemotherapy (IFO, carboplatin, ICE, alternating with CDDP and CD.

1 (6.6%) PR, 1 (6.6%) CLR

2- and 5-year EFS rates 7% & 4%, resp, 2- and 5-year OS rates 44% and 22%, resp.

Basaran M, et al Oncology;72:255-60 [72]

Epirubicin 90 mg/m² cisplatin 100 mg/m² on day 1 and IFO 2.0 g/m² day with an equivalent dose of mesna on days 2-4, repeated every 21 days

10 (26%) CR, 5 year DFS 41.9%, OS 48.2%.

Iwamoto Y, et al J Orthop Sci 14:397-04. [73]

Preoperative chemotherapy: HD-MTX, CDDP, and ADR.

5 year OS 77.9%

5 year EFS 65.5%

Berger M, et al Cancer 115: 2980 -7. [74]

Cyclophosphamide 4 g/m² on Day 1 followed by etoposide at 200 mg/m² on Days 2, 3, and 4.

9 (35%) SD, OS at 1 yr 50%, PFS 42%

Chawla S P, et al Mol Ther. 17:1651-7. [51]

Escalating doses of Rexin-G i.v from 8 × 10¹¹ to 24 × 10¹¹ colony forming units (cfu)/cycle.

10 (58.8%) SD

3 (50%) SD(lowest dose)

10 (71%) SD(higher dose)